Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
FOMX was delisted on the 6th of March, 2020.
56 hedge funds and large institutions have $102M invested in Foamix Pharmaceuticals Ltd. Ordinary Shares in 2017 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 20 increasing their positions, 13 reducing their positions, and 18 closing their positions.
54% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 13
10% less capital invested
Capital invested by funds: $113M → $102M (-$11.5M)
16% less funds holding
Funds holding: 67 → 56 (-11)
56% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 18
96% less call options, than puts
Call options by funds: $9K | Put options by funds: $206K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$4.91M |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$2.83M |
| 3 |
MWNA
Marshall Wace North America
New York
|
+$845K |
| 4 |
IBT
International Biotechnology Trust
London,
United Kingdom
|
+$719K |
| 5 |
Bank of New York Mellon
New York
|
+$678K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$9.01M |
| 2 |
O
OppenheimerFunds
New York
|
-$2.71M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
-$1.32M |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.2M |
| 5 |
EU
Emory University
Atlanta,
Georgia
|
-$1.01M |
FOMX Hedge Fund Activity: Q2 2017 in Review
56 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) for Q2 2017, worth a combined $102M — down 10% from $113M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of FOMX and 8 opened new positions — a net loss of 10 holders — while 13 trimmed existing stakes and 20 added.
The largest buyer was Great Point Partners, adding an estimated $4.91M. The largest seller was RA Capital Management, exiting entirely with an estimated $9.01M sold.
- 56 institutional investors held Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) as of Q2 2017, down from 67 in Q1 2017.
- Funds reported $102M of Foamix Pharmaceuticals Ltd. Ordinary Shares stock for Q2 2017, down 10% quarter-over-quarter.
- 8 funds opened new Foamix Pharmaceuticals Ltd. Ordinary Shares positions in Q2 2017 and 18 closed out, a net change of -10 holders.
- The largest Foamix Pharmaceuticals Ltd. Ordinary Shares buyer in Q2 2017 was Great Point Partners, an estimated $4.91M added.
- The largest Foamix Pharmaceuticals Ltd. Ordinary Shares seller in Q2 2017 was RA Capital Management, an estimated $9.01M sold.
Based on aggregated 13F filings for Q2 2017.